Loading...
3 results
Search Results
Now showing 1 - 3 of 3
- p53 as the Focus of Gene Therapy: Past, Present and FuturePublication . Valente, Joana; Queiroz, João; Sousa, FaniSeveral gene deviations can be responsible for triggering oncogenic processes. However, mutations in tumour suppressor genes are usually more associated to malignant diseases, with p53 being one of the most affected and studied element. p53 is implicated in a number of known cellular functions, including DNA damage repair, cell cycle arrest in G1/S and G2/M and apoptosis, being an interesting target for cancer treatment.
- The biological performance of purified supercoiled p53 plasmid DNA in different cancer cell linesPublication . Valente, J. F. A.; Sousa, A.; Gaspar, V. M.; Queiroz, João; Fani, SousaTumor suppressor p53 remains one of the most interesting therapeutic targets in cancer gene therapy due to itsconsistent mutation in numerous cancers. Thus, the reinstatement of the p53 expression and function can be seenas an effective alternative for cancer treatment, motivating research in thisfield. In this study,L-methioninematrix was used to purify the supercoiled topoisoform of a plasmid DNA encoding the p53 protein. This purebiopharmaceutical was conjugated with liposomes to comprehensively analyze itsin vitroperformance andtherapeutic potential in different cancer cell lines, including the lung and cervix models. A different profile ofcellular responses was attained after the transfection of these cancer cell lines with the p53-pDNA. Actually, thein vitrotransfection with pure sc p53-pDNA resulted in a higher expression of the tumor suppressor protein incancer cells when compared with the native pDNA samples (oc + sc topoisoforms). Also, wild-type p53 ex-pression following transfection was significantly higher in HeLa cervix cancer cells compared to that obtained inA549 lung cancer cells. Overall, ourfindings emphasize the potential of sc pDNA gene-based therapy, alsoraising awareness of the need to adjust the therapeutics, considering the feature of high heterogeneity of cancer cells.
- DoE to improve supercoiled p53-pDNA purification by O-phospho-l-tyrosine chromatographyPublication . Valente, Joana; Sousa, A.; Queiroz, João; Sousa, FaniP53 is implicated in various cellular functions and several studies have shown that transfection of cancer cells with wild-type p53-expressing plasmids could directly drive cells into growth arrest and/or apoptosis. In the present work, the 6.07 kbp pcDNA3-FLAG-p53 plasmid, which encodes the p53 tumor suppressor, was produced and recovered from a recombinant cell culture of Escherichia coli DH5α. Following plasmid biosynthesis, the O-phospho-l-tyrosine chromatographic matrix was explored to purify the supercoiled p53-encoding plasmid. In order to quickly determine the optimal chromatographic performance and to obtain the required purity degree, maximizing the recovery yield of the supercoiled plasmid DNA, the Composite Central Face design was applied. The model revealed to be statistically significant (p-value < 0.05), with coefficient of determination of 0.9434 for the recovery yield and 0.9581 for purity and the central point was successfully validated. After the chromatographic process optimization by using the design of experiments tool, 49.7% of the supercoiled p53-encoding plasmid was recovered with 98.2% of purity, when a decreasing ammonium sulphate gradient was applied. The dynamic binding capacity of the O-phospho-l-tyrosine agarose column was 0.35 ± 0.02 mg pDNA/mL matrix at 50% of the breakthrough. Finally, the purified sample was analysed to assess the content of endotoxins, proteins and genomic DNA, showing that all these impurity levels were below the recommendations of the regulatory agencies.